CagriSema for weight loss: interpreting REDEFINE 1
Cagrilintide–semaglutide has randomized evidence for weight reduction in adults with obesity, or overweight with associated conditions. The trial result is a group estimate under defined study conditions, not a promise for an individual.
By PurePeptideHub Editorial Team · Updated . Educational source review; independent clinical review pending.
The evidence behind the claim
In REDEFINE 1, 3,417 adults were randomized. Estimated mean weight change at 68 weeks was −20.4% with cagrilintide–semaglutide and −3.0% with placebo.
References: [1]
Which estimate are you reading?
REDEFINE 1 reports a treatment-policy estimate that accounts for the randomized treatment strategy, including treatment changes or discontinuation. Headlines using other estimands can show different numbers. Compare like with like and identify whether an estimate assumes continued treatment.
What the trial does not establish
Participants did not have diabetes, and the study included a lifestyle intervention. The result does not establish suitability for everyone seeking cosmetic weight loss, superiority to every other medicine or equivalence of vendor-made mixtures. Adverse events and discontinuations belong alongside the weight result.
Sources and further reading
Important Considerations
- !Match the exact compound, route, study population and measured outcome before applying a research finding.
- !This source review does not establish an individual treatment plan. Discuss clinical questions with a qualified healthcare professional.
Frequently Asked Questions
Is a 20.4% mean loss a guaranteed personal result?
No. It is an estimated average for the studied group at 68 weeks. Individual outcomes varied, and a clinician must assess the relevant treatment options.
Does the study validate any product labeled CagriSema?
No. Evidence applies to the studied preparation and protocol. Current approval, availability and product identity must be checked separately.